Stage-specific roles of clonally expanded CD8<sup>+</sup> T cells in regulating amyloid pathology in Alzheimer's disease models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41145447.
- Also identified by DOI 10.1038/s41467-025-64503-x and PMC identifier 12559718.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clonally expanded CD8<sup>+</sup> T cells may contribute to Alzheimer's disease (AD) pathology through interactions with brain-resident cells. However, the functional impact of AD-specific T cell receptor (TCR) clonotypes remains unclear. Here, we demonstrate that CD8<sup>+</sup> T cells undergo clonal expansion in early-stage AD mouse models, App<sup>NL-G-F</sup> and 5xFAD, and that their depletion reduces amyloid plaque accumulation. Expanded TCR-expressing CD8<sup>+</sup> T cells preferentially infiltrate the brain, exacerbating plaque deposition. Moreover, brain-infiltrating CD8<sup>+</sup> T cells impair microglial transition into disease-associated states, suppressing amyloid clearance via CCL5-CCR5 signaling. Pharmacological blockade of CCL5 attenuates amyloid deposition, whereas CCL5 administration aggravates pathology. Notably, T cell depletion at later disease stages exacerbates amyloid pathology, suggesting a temporal shift in their function. Early-stage CD8<sup>+</sup> T cells exhibit cytotoxic and effector profiles, whereas late-stage cells acquire tissue-resident and exhausted phenotypes. This temporal switch-from pathogenic to protective roles-highlights the stage-specific contribution of CD8<sup>+</sup> T cells to AD and their potential as therapeutic targets.
Medical subject headings
- Alzheimer Disease
- CD8-Positive T-Lymphocytes
- Plaque, Amyloid